Drug intelligence / Profile preview

h5n1 pisv

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

H5N1 pISV (pandemic inactivated subunit vaccine) is an inactivated vaccine designed to prevent infection caused by the H5N1 influenza virus subtype, commonly known as avian or bird flu. It works by stimulating the immune system to produce antibodies against the H5N1 virus. Research indicates it can be particularly effective when used in a prime-boost approach following administration of a pandemic live attenuated influenza vaccine (pLAIV), generating robust humoral responses.

Other names: H5N1-pISVH-5N1-pISVH 5N1-pISVpandemic inactivated subunit vaccine

Targets

BCR (Immunoglobulin G B Cell Receptor)TCR (T cell antigen receptor complex)

Beyond the preview

Go deeper on h5n1 pisv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on h5n1 pisv.

Explore the full profile